Photoselective vaporization for prostatic obstruction with the 120-W lithium triborate laser: 1-year clinical outcomes.

Autor: Woo HH; Sydney Medical School, Sydney Adventist Hospital Clinical School, University of Sydney, and Department of Urology, Sydney Adventist Hospital, Sydney, New South Wales, Australia. hwoo@urologist.net.au, Hossack TA
Jazyk: angličtina
Zdroj: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2011 Feb; Vol. 18 (2), pp. 162-5. Date of Electronic Publication: 2011 Jan 10.
DOI: 10.1111/j.1442-2042.2010.02686.x
Abstrakt: There are few reports of the clinical outcomes of photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) using the 120-W lithium triborate (LBO) laser. The present study evaluates clinical outcomes of 76 men treated with the 120-W LBO laser by an experienced PVP surgeon with 12 months follow up. The International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and post-void residual (PVR) were examined at baseline and at 3 and 12 months. These parameters at baseline and 12 months were 20 ± 7.0, 7.6 ± 3.5 mL/s, 155 ± 155 mL and 8.1 ± 6.1, 22.5 ± 10.3 mL/s, 59 ± 87 mL, respectively. Clinically, meaningful improvements in IPSS, Qmax and PVR were observed at 3 months and sustained at 12 months. There were few adverse events, with only 5.3% of patients requiring recatheterization. Clinical outcome at 12 months was similar to that at 3 months and to other published series.
(© 2011 The Japanese Urological Association.)
Databáze: MEDLINE